Date: 2017-08-18
Type of information: Licensing agreement
Compound: MIV-802
Company: Medivir (Sweden) Ascletis (China)
Therapeutic area: Infectious diseases
Type agreement: licensing
Action mechanism:
- NS5B polymerase inhibitor/enzyme inhibitor/nucleotide analog. MIV-802 is a highly potent, pangenotypic nucleotide-based inhibitor of the HCV NS5B polymerase, which recently entered preclinical development. Preclinical data indicate that MIV-802 can be used effectively in combination with other classes of antiviral agents for the treatment of HCV, including protease inhibitors and NS5A inhibitors.
Disease: hepatitis C
Details:
- • On August 18, 2017, Medivir and Ascletis announced that Ascletis has licensed the exclusive rights to develop, manufacture and commercialize Medivir’s nucleotide polymerase inhibitor for hepatitis C, MIV-802 (Ascletis code: ASC21), in Greater China. “Ascletis has filed an NDA in China for its first HCV NS3/4A medicine, danoprevir, at the end of 2016 and has an HCV NS5A inhibitor in the late stage clinical development. By acquiring MIV-802, a nucleotide NS5B inhibitor, Asceltis is committed to treating, eventually eliminating, hepatitis C in greater China with its multiple leading antiviral combinations including MIV-802,” said Dr. Jinzi J. Wu, CEO of Ascletis.
Financial terms:
- Under the terms of the agreement, Medivir received an upfront payment, and is entitled to receive milestones based on successful development through commercial launch and tiered royalties on net sales of MIV-802 containing products. Ascletis will fund clinical development, manufacturing and commercialization of MIV-802 in Greater China.
Latest news:
Is general: Yes
